Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals

Name Change:
Aeterna Zentaris Inc. has officially changed its name to COSCIENS Biopharma Inc. as of August 6, 2024.

Company Focus:
COSCIENS Biopharma is a specialty biopharmaceutical company focused on commercializing and developing therapeutics and diagnostic tests.

Lead Product:
The company's lead product is Macrilen (macimorelin), used for the diagnosis of adult growth hormone deficiency (AGHD). Sales of Macrilen are currently discontinued in the U.S. market until a new commercialization partner is identified.

Strategic Partnerships:
COSCIENS Biopharma is actively seeking strategic development and commercialization partners to enhance its product offerings and market reach.

Rebranding Significance:
The name change reflects the company's evolving focus and commitment to advancing in the biopharmaceutical industry.